Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study

Table 3 Adverse reactions of anlotinib combined with nab-ptx in second-line or above treatment for advanced gastric cancer, n (%)

Adverse events	Any grade	Grade 3 or 4
Hematological
Leukopenia	13 (36.11)	2 (5.56)
Neutropenia	12 (33.33)	2 (5.56)
Thrombocytopenia	11 (30.56)	2 (5.56)
To anemia	10 (27.78)	0
Non-hematologic
Decreased appetite	19 (52.78)	0
Fatigue	16 (44.44)	0
Hypertension	11 (30.56)	2 (5.56)
Hand-foot syndrome	12 (33.33)	2 (5.56)
Proteinuria	9 (25.00)	2 (5.56)
Peripheral neuropathy	7 (19.44)	1 (2.78)
Elevated transaminase	7 (19.44)	1 (2.78)
Oral ulcer	6 (16.67)	0
Stomatitis	5 (13.89)	0
Abdominal pain	5 (13.89)	0
Diarrhea	5 (13.89)	0
Hyperbilirubinemia	3 (8.33)	0
Elevated LDH	3 (8.33)	0
ALP increased	3 (8.33)	0
Elevated GGT	3 (8.33)	0
Hypoproteinemia	4 (11.11)	0
Dysphagia	3 (8.33)	0
Dysphonia	3 (8.33)	0
Bleeding	0	0

LDH: Lactate dehydrogenase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase.